A multi-center, development, dose-escalation clinical study to evaluate the safety, tolerability, and pharmacokinetic characteristics of MB07133 for injection
Latest Information Update: 24 Oct 2024
At a glance
- Drugs MB 7133 (Primary)
- Indications Carcinoma; Cholangiocarcinoma; Liver cancer
- Focus Adverse reactions
- Sponsors Xian Xintong Pharmaceutical Research
- 24 Oct 2024 Status changed from active, no longer recruiting to completed.
- 05 Mar 2020 New trial record